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though the different ways in which one condition causes the
other are not known. Some studies have suggested that in
patients with chronic HCV+ hepatitis, the whole panel of auto-
antibodies (AMA, ANA, anti-SMA, anti-LKM) could affect the
response to interferon and clinical proﬁle of liver disease.6
However, when ANA was analysed separately, it did not appear
to conﬁrm these assumptions.5 Fortunately, it seems that the
presence of these ANAs in HCV+ patients with or without IFN
is not related to IFN efﬁcacy.3
Our patient became positive only for ANA, remaining neg-
ative for the rest of the antibodies related to both lupus and
AIH. She has not developed either of these clinical syndromes
or classical viral relapse (occult HCV not analysed). Although
she has not had a liver biopsy at any time, currently, we  see no
justiﬁcation for monitoring these antibodies unless she shows
clinical or biochemical abnormalities of some form.
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2006;86:390–3 [article in Chinese].treatment, ANA not only bears the possibility of developing
SLE, but could also be related with the hepatic infection itself.
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whose clinical or analytical ﬁndings are unrelated to hepati-
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Dear Editor:
We  hereby thank Dr Martín-Gómez for her interest in our arti
cle “Infection with hepatitis C virus, interferon  and lupus
An odd association”1 and her comment on it.As she clearly explains in her remark, the presence of
antinuclear antibodies (ANA) among patients with chronic
HCV infection has been extensively described in the literature
as an immune epiphenomenon lacking clinical signiﬁcance in
most cases.2
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Additional supporting tests, including extending the
autoantibody proﬁle, should only be performed in patienttario de «Infección por virus de la hepatitis C, interferón  y lupus,
hepatitis or drug-induced lupus.
Following treatment, our patient had fever, asthenia, and
arthralgia, as well as positive anti-histone antibodies. The
temporal relationship between concomitant interferon treat-
ment and negative HCV tests resulted in the diagnosis and
subsequent therapy of the patient.
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By contrast, the advent of new drugs for the treatment of
CV, such as the nucleotide NS5B polymerase inhibitor, sofos-
uvir, and the NS5A inhibitor, daclatasvir, paves the way for
terferon-free treatments. These new drugs will avoid the
terferon-associated adverse effects, while achieving highly
stained virologic response rates. However, further stud-
s should be conducted in special populations,3 including
atients with end-stage renal disease undergoing haemodial-
is.
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